骨密度相关全基因组多基因评分在识别骨质疏松性骨折高风险个体中的临床效用
本研究构建并验证股骨颈和全身骨密度的全基因组多基因评分,在455,663名欧洲血统英国生物银行个体中外部测试其单独及联合临床风险因素识别骨质疏松性骨折高风险的能力。结果显示全基因组多基因评分每降低一个单位,骨折风险最高增加1.17倍;与FRAX基础模型相比,加入多基因评分可改善骨折再分类。
要点
- 全基因组多基因评分每降低一个单位,骨折风险最高增加1.17倍(HR 1.17,95%CI 1.15-1.19,p<0.0001)。
- 与FRAX基础模型相比,加入多基因评分的模型改善骨折再分类最高达2.2%(95%CI 2.1-2.4%)。
- 高效多基因评分可识别骨折发生率差异高达1.5倍的 strata,将多基因评分纳入临床诊断有望增加人群筛查获益。
核心结论
- 高效多基因评分估计可识别骨折发生率差异高达1.7倍的 strata,将多基因评分信息纳入临床诊断有望增加人群筛查项目的获益。
研究设计与样本
- 构建并验证股骨颈和全身骨密度的全基因组多基因评分,在英国生物银行455,663名欧洲血统个体中进行外部测试,单独及联合可用临床风险因素评估,并与既往发表的限制性多基因评分比较预测准确性。
主要发现
- 全基因组多基因评分每降低一个单位,与骨折风险最高增加1.17倍相关。
- 四种多基因评分中,[公式见原文]与 incident fracture 关联最弱(HR 1.03;95%CI 1.01-1.05,p=0.001),[公式见原文]关联最强(HR 1.17;95%CI 1.15-1.19,p<0.0001)。
- 与FRAX基础模型相比,加入[公式见原文]、[公式见原文]、[公式见原文]和[公式见原文]的模型分别改善骨折再分类1.2%(95%CI 1.0-1.3%)、0.2%(95%CI 0.1-0.3%)、1.4%(95%CI 1.3-1.5%)和2.2%(95%CI 2.1-2.4%)。
关键数值与推荐
- 全基因组多基因评分每降低一个单位,骨折风险最高增加1.17倍。
- 四种多基因评分中,[公式见原文]的HR为1.03(95%CI 1.01-1.05,p=0.001),[公式见原文]的HR为1.17(95%CI 1.15-1.19,p<0.0001)。
- 与FRAX基础模型相比,加入[公式见原文]、[公式见原文]、[公式见原文]、[公式见原文]的模型改善骨折再分类分别为1.2%(95%CI 1.0-1.3%)、0.2%(95%CI 0.1-0.3%)、1.4%(95%CI 1.3-1.5%)、2.2%(95%CI 2.1-2.4%)。
临床怎么用
- 作者认为,将多基因评分信息纳入临床诊断有望增加人群筛查项目的获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The potential of bone mineral density (BMD)-related genome-wide polygenic score (PGS) in identifying individuals with a high risk of fractures remains unclear. This study suggests that an efficient PGS enables the identification of strata with up to a 1.5-fold difference in fracture incidence. Incorporating PGS into clinical diagnosis is anticipated to increase the population-level screening benefits. PURPOSE: This study sought to construct genome-wide polygenic scores for femoral neck and total body BMD and to estimate their potential in identifying individuals with a high risk of osteoporotic fractures. METHODS: Genome-wide polygenic scores were developed and validated for femoral neck and total body BMD. We externally tested the PGSs, both by themselves and in combination with available clinical risk factors, in 455,663 European ancestry individuals from the UK Biobank. The predictive accuracy of the developed genome-wide PGS was also compared with previously published restricted PGS employed in fracture risk assessment. RESULTS: For each unit decrease in PGSs, the genome-wide PGSs were associated with up to 1.17-fold increased fracture risk. Out of four studied PGSs, [Formula: see text] (HR: 1.03; 95%CI 1.01-1.05, p = 0.001) had the weakest and the [Formula: see text] (HR: 1.17; 95%CI 1.15-1.19, p < 0.0001) had the strongest association with an incident fracture. In the reclassification analysis, compared to the FRAX base model, the models with [Formula: see text], [Formula: see text], [Formula: see text], and [Formula: see text] improved the reclassification of fracture by 1.2% (95% CI, 1.0 to 1.3%), 0.2% (95% CI, 0.1 to 0.3%), 1.4% (95% CI, 1.3 to 1.5%), and 2.2% (95% CI, 2.1 to 2.4%), respectively. CONCLUSIONS: Our findings suggested that an efficient PGS estimate enables the identification of strata with up to a 1.7-fold difference in fracture incidence. Incorporating PGS information into clinical diagnosis is anticipated to increase the benefits of screening programs at the population level.
引用
- Xiao X, Wu Q. The clinical utility of the BMD-related comprehensive genome-wide polygenic score in identifying individuals with a high risk of osteoporotic fractures. Osteoporos Int. 2023. PMID: 36622390. doi:10.1007/s00198-022-06654-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。